Login:
 
Practitioner 2009;253(1717):16

Weighing up risks and benefits of antidepressants

25 Apr 2009Pais-up subscribers

My current first choice antidepressant is citalopram (moderate efficacy, high acceptability, low suicide risk, intermediate half-life). While I might be tempted to consider switching to sertraline, I am not yet convinced that this would achieve a clinically significant benefit.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .